Treatment patterns and effectiveness of patients with multiple myeloma initiating Daratumumab across different lines of therapy: a real-world chart review study

BACKGROUND: Daratumumab, a CD38 monoclonal antibody, has demonstrated efficacy as monotherapy and combination therapy across several indications, both among newly-diagnosed and refractory patients with multiple myeloma (MM). However, there is limited evidence on treatment patterns and effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales: ATRASH, Shebli, THOMPSON-LEDUC, Philippe, TAI, Ming-Hui, KAILA, Shuchita, GRAY, Kathleen, GHELERTER, Isabelle, LAFEUILLE, Marie-Hélène, LEFEBVRE, Patrick, ROSSI, Adriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590284/
https://www.ncbi.nlm.nih.gov/pubmed/34772368
http://dx.doi.org/10.1186/s12885-021-08881-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590284/
https://www.ncbi.nlm.nih.gov/pubmed/34772368
http://dx.doi.org/10.1186/s12885-021-08881-7

Ejemplares similares